ImmuCell Finalizes Executive Employment Agreements and Grants Significant Equity Incentives
Summary
ImmuCell announced new employment agreements and substantial equity grants for its CFO, SVP Sales & Marketing, and CEO, aiming to retain key executives and incentivize performance.
Key Events
-
New Employment Agreements
CFO Timothy C. Fiori and SVP Sales & Marketing Bobbi Jo Brockmann entered into new employment agreements, effective January 27, 2026, with annual base salaries of $315,000 and $300,000, respectively, plus target cash bonuses.
-
Significant Equity Grants to Executives
Mr. Fiori received 120,000 stock options and Ms. Brockmann received 100,000 stock options, both exercisable at $6.26 per share and vesting over three years. CEO Olivier te Boekhorst received a performance-based grant of 110,000 options at $6.265 per share.
-
Performance-Based CEO Incentive
The CEO's 110,000 stock options vest only upon achieving a challenging financial target: net operating income for four consecutive quarters exceeding 300% of the 2025 fiscal year's audited net operating income.
Analysis
ImmuCell Corporation has entered into new employment agreements with its Chief Financial Officer, Timothy C. Fiori, and Senior Vice President of Sales and Marketing, Bobbi Jo Brockmann, effective January 27, 2026. These agreements include annual base salaries of $315,000 and $300,000, respectively, along with target annual cash bonuses of 50% of their base salaries. Additionally, both executives received stock option grants of 120,000 shares for Mr. Fiori and 100,000 shares for Ms. Brockmann, exercisable at $6.26 per share and vesting over three years. CEO Olivier te Boekhorst also received a performance-based stock option grant of 110,000 shares, exercisable at $6.265 per share, which vests only if the company's net operating income for four consecutive quarters exceeds 300% of its 2025 fiscal year's audited net operating income. These compensation packages are designed to retain key talent and align executive incentives with long-term shareholder value, though the equity grants represent a notable potential dilution.
At the time of this filing, ICCC was trading at $6.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.3M. The 52-week trading range was $4.28 to $7.60. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.